Cocaine use disorder (CUD) remains a debilitating health problem in the United States for which there are no Food and Drug Administration-approved treatment options. Accumulating anatomical and electrophysiological evidence indicates that the muscarinic acetylcholine receptor (mAChR) subtype 5 (M 5 ) plays a critical role in the regulation of the mesolimbic dopaminergic reward circuitry, a major site of action for cocaine and other psychostimulants. In addition, M 5 knockout mice exhibit reduced cocaine self-administration behaviors with no differences in sugar pelletmaintained responding relative to wild-type mice. These findings suggest that selective inhibition of M 5 mAChR may provide a novel pharmacological approach for targeting CUD. Recently, we reported the synthesis and characterization of ML375, a selective negative allosteric modulator (NAM) for the rat and human M 5 mAChR with optimized pharmacokinetic properties for systemic dosing in rodents. In the present study, male Sprague-Dawley rats were trained to selfadminister intravenous cocaine (0.1-0.75 mg/kg/infusion) under a 10-response fixed ratio or a progressive ratio schedule of reinforcement. Under both schedules of reinforcement, ML375 produced dose-related reductions in cocaine self-administration. ML375 also modestly reduced sugar pellet-maintained responding on the 10-response, fixed ratio schedule but had no effect under a progressive ratio schedule of reinforcement. Further, ML375 did not affect general motor output as assessed by a rotarod test. Collectively, these results provide the first demonstration that selective inhibition of M 5 using the M 5 NAM ML375 can attenuate both the reinforcing effects and the relative strength of cocaine and suggest that M 5 NAMs may represent a promising, novel treatment approach for CUD.
INTRODUCTION
Cocaine use disorder (CUD) is a major ongoing health problem within the United States and characterized by compulsive cocaine use, dependence and repeated relapse after periods of abstinence (SAMHSA 2015) . On the basis of the 2014 National Survey on Drug Use and Health, it is estimated that approximately 1.5 million individuals 12 years or older are current cocaine users (SAMHSA 2015) . Despite the considerable negative impact of CUD on individuals and their families, there remains no Food and Drug Administration-approved pharmacological treatment for CUD (Shorter et al. 2015; Czoty et al. 2016) .
Previous studies have shown that the reinforcing effects of cocaine are attributed to acute and long-term pathophysiological adaptations in the canonical mesocorticolimbic dopamine (DA) reward circuitry that persist into abstinence and contribute to the high rates of drug craving and relapse (Nestler 2005; Korpi et al. 2015) . The mesocorticolimbic reward circuitry consists of midbrain DA cell bodies located in the ventral tegmental area (VTA) and their respective projection targets, including the nucleus accumbens (NAc) and prefrontal cortex (Nestler 2005) . To date, several pharmacological strategies targeting modulation of mesolimbic DA circuitry have been under investigation in clinical populations of cocaine addicts, including indirect DA agonists and selective D 2 DA receptor antagonists as substitution or detoxification approaches, respectively (Shorter et al. 2015; Castells et al. 2016) . Unfortunately, these therapeutic strategies have not resulted in successful treatments in part because of the risk of abuse liability and/or cardiovascular effects with indirect DA agonists and the dose-limiting adverse effects on motor function associated with D 2 DA receptor antagonists (Platt et al. 2002; Verrico et al. 2013; Negus & Henningfield 2015; Shorter et al. 2015; Castells et al. 2016) . Thus, identification and validation of novel therapeutic targets that can modulate aspects of the mesocorticolimbic reward circuitry to selectively reduce cocaine-taking behaviors without unwanted side effects represent a critical unmet need.
One such alternative approach for the treatment of CUD may involve the selective modulation of the muscarinic acetylcholine receptor (mAChR) subtype 5 (M 5 ) (Langmead et al. 2008) . Of the five mAChR subtypes (termed M 1 -M 5 ), only M 5 is expressed at high levels in ventral midbrain structures, including the VTA and substantia nigra (Vilaro et al. 1990; Weiner et al. 1990; Yasuda et al. 1993) . Previous studies have reported increased VTA DA cell firing and extracellular DA release in the NAc following electrical stimulation of cholinergic neurons of the laterodorsal tegmental and pedunculopontine tegmental nuclei that project to the VTA are absent in M 5 knockout (KO) mice (Blaha et al. 1996; Forster & Blaha 2000; Forster et al. 2002; Steidl et al. 2011) . Moreover, the reinforcing effects and the relative strength of cocaine were robustly reduced in the M 5 KO mice (Fink-Jensen et al. 2003; Thomsen et al. 2005) . Importantly, the M 5 KO mice exhibited no deleterious effects on food-maintained behavior or basic behavioral and physiological measures such as body weight, sleep and sensorimotor output (Fink-Jensen et al. 2003; Thomsen et al. 2005) . Taken together, these data suggest that M 5 is critically involved in the regulation of midbrain DA neuronal activity and that development of selective M 5 antagonists might represent an important strategy for the attenuation of the acute and/or long-term pathophysiological adaptations induced by cocaine within the mesocorticolimbic reward circuitry thought to underlie CUD. However, further investigation into the role of M 5 has been hindered by the lack of selective compounds targeting M 5 .
Recently, we reported the discovery and optimization of the first negative allosteric modulator (NAM) for the M 5 mAChR, ML375 (Gentry et al. 2013 ). This compound is highly selective for the rat and human M 5 mAChR receptor. Importantly, this compound does not bind to the highly conserved orthosteric binding site of acetylcholine and instead binds to an allosteric site (Gentry et al. 2013) . Furthermore, ML375 has a favorable drug metabolism and pharmacokinetics profile across multiple species with high CNS penetration, representing the first in vivo compound to allow examination of the M 5 receptor for addiction-related behaviors (Gentry et al. 2013) . In the present study, we evaluated the effects of ML375 on cocaine self-administration and sugar pellet-maintained responding under fixed ratio (FR) and progressive ratio (PR) schedules of reinforcement to examine the role for M 5 mAChRs in modulating drug and nondrug-related behavior. We also utilized the rotarod test to examine effects on an unconditioned measure of motor function. ML375 reduced cocaine self-administration under FR and PR schedules of reinforcement; however, ML375 did not affect sugar pellet-maintained responding under a PR schedule or unconditioned motor activity. These data support our hypothesis that inhibition of M 5 can selectively affect cocaine-related behaviors without impairing behaviors not associated with drug use.
MATERIALS AND METHODS

Drugs
Cocaine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.9 percent saline solution. ML375 was synthesized in house and was first dissolved in 100 percent Dimethyl sulfoxide (DMSO) and administered as an aqueous 20 percent (w/v) 2-hydroxypropyl-β-cyclodextrin and 5 percent DMSO microsuspension. Cocaine was administered intravenously (i.v.); ML375 and its vehicle were administered intraperitoneally (i.p.) in a volume of 2 ml/kg.
Subjects
Twenty male Sprague-Dawley rats (Envigo, Indianapolis, IN, USA) were approximately 70 days old upon arrival at the facility and weighed between 260 and 300 g at the onset of the study. Rats were single housed under a 12/12-hour light/dark cycle with ad libitum access to water. Rats were maintained at 85 percent of their free feeding weight for the duration of the study based on a standard growth curve and fed with standard rodent chow (Harlan Teklad, Madison, WI, USA). Housing conditions and all experimental procedures were approved by Vanderbilt University's Institutional Animal Care and Use Committee and were conducted in accordance with the National Research Council's Guide for Care and Use of Laboratory Animals (8th edition, 2011).
Apparatus
All behavioral testing was conducted during the first half of the light portion of the light/dark cycle, between 0900 and 1100 hours. Sessions were run in modular operant chambers, equipped with two retractable levers, a stimulus light above each lever and a house light located on the opposite wall (Med Associates, St. Albans, VT, USA). Chambers were located in sound-attenuating cabinets equipped with fans to provide ventilation and mask external noise. For the cocaine self-administration sessions, a spring-leash tether connected to the vascular access buttons on the rat housed the infusion line through which drug infusions were delivered via an infusion pump (Razel Model A) located outside of the operant chamber.
COCAINE SELF-ADMINISTRATION
Surgical procedure
Rats were anesthetized with isoflurane, and a polyurethane catheter (Instech Laboratories, Plymouth Meeting, PA, USA) was implanted into the right jugular vein. The catheter was connected to a vascular access button (Instech Laboratories), which was located on the back just caudal to the scapula. Rats were allowed to recover from surgery for 7 days, and catheters were flushed with Baytril (0.23 mg/ml) followed by 0.1 ml of heparinized saline (30 IU/ml) daily to maintain catheter patency and prevent infection. Carprofen (5 mg/kg, s.c.) was given postoperatively for 7 days for analgesic support. Catheter patency was verified daily with pre-session and post-session flushing of catheters. The resistance to flow was used as the first indicator of possible catheter occlusion. If catheter occlusion was suspected, 0.1 ml ketamine (15 mg/ml) was administered and loss of muscle tone within 5 seconds was used to indicate a patent catheter. If catheter patency was lost, that test day's data point was excluded and the rat was excluded from selfadministration studies until a left jugular catheter was implanted. Following 7 days of postoperative care, rats were returned to self-administration sessions. Reacquisition of stable cocaine self-administration on average occurred within a week. If the second catheter lost patency, the rat was removed from the study.
Experiment 1: cocaine and sugar pellet self-administration maintained under a fixed ratio schedule of reinforcement Self-administration procedures have been described elsewhere (Gould et al. 2016) . Briefly, sessions started with a priming infusion of cocaine followed by extension of two levers, indicating the availability of the drug. Initially, a single response on the active lever (fixed ratio 1; FR1) resulted in the retraction of both levers, illumination of the stimulus light above the active lever and infusion of 0.5 mg/kg cocaine over a duration of time dependent upon the weight of the rat (3-4 seconds). The stimulus light remained on during and for an additional second after the infusion, during which responses were recorded but had no consequences. After the light turned off, levers were extended again, signaling the availability of cocaine. Once the rat received >10 infusions for two consecutive days, the response requirement was gradually increased to FR10. Sessions lasted 2 hours in length or until 60 reinforcers were earned, 5 days a week. Stable self-administration was defined as >10 infusions per day for three consecutive days and <25 percent variability in the number of infusions with no upward or downward trends evident. All rats achieved these criteria within 14 sessions. The location (left or right) of the active and inactive lever was counterbalanced for the cohort. Once stability was obtained, test sessions commenced to examine the effects of ML375 (10 or 30 mg/kg) on the training dose of cocaine, administered 15 minutes prior to the start of the session.
On the basis of the results from this first study, we next examined the effects of 30 mg/kg of ML375 on multiple doses of the cocaine dose-response curve (0.1-0.75 mg/kg/infusion of cocaine or saline and dose order randomized per animal). The same cohort of rats as described earlier self-administered each cocaine dose until responding stabilized for three consecutive days followed by a test session in which rats were administered 30 mg/kg of ML375 (i.p.) 15 minutes before the start of the session. The same dose of cocaine was always available 24 hours after each test session to assess any longterm effects on behavior. Animals were then returned to the maintenance dose of cocaine (0.5 mg/kg/infusion) until responding stabilized (within 1-2 days); at which point, another dose of cocaine was substituted.
To examine the potential nonselective effects of ML375, we employed a similar research design to assess the effects of ML375 on sugar pellet-maintained responding. Rats were initially trained to make a single response (FR1) and then increased to an FR10 schedule with completion of each ratio resulting in the delivery of a single 45-mg sugar pellet (Bio-Serve, Flemington, NJ, USA) and illumination of a stimulus light above the active lever for 10 seconds. After 10 seconds, the stimulus light turned off, signaling the availability of the next reinforcer. Following stable responding, the training session commenced during which rats received an i.p. injection of saline before the start of the session. Following stable responding (average number of reinforcers < 20 percent across the preceding three training sessions, with no upward or downward trend), test sessions were initiated. The test sessions were identical to training sessions except that rats received an i.p. injection of vehicle or ML375 (10 or 30 mg/kg) 15 minutes before the start of the session. Once animals met stability criteria, another test session was conducted. Sessions lasted for 120 minutes or until 100 reinforcers were earned, 5 days a week with a minimum of 5 days between test sessions. Experiment 2: cocaine and sugar pellet self-administration maintained under a progressive ratio schedule of reinforcement Following the completion of experiment 1, rats with patent catheters self-administered cocaine (0.1-0.75 mg/kg/infusion) under a PR schedule of reinforcement in which the response requirement for delivery of each reinforcer increased as determined by the exponential equation used by Richardson and Roberts (1996) , ratio = [5 × e(R × 0.2)] À 5. The first 10 ratios given by this equation are 1, 2, 4, 6, 9, 12, 15, 20, 25 and 32 . Sessions terminated when 20 minutes had elapsed without completion of the current ratio requirement; the final completed ratio was termed the break point. Stable responding was defined as >10 reinforcers per session for three consecutive sessions and <25 percent variability in the number of reinforcers with no upward or downward trends evident. Once stability had been achieved, rats were injected i.p. with ML375 (10 or 30 mg/kg) or vehicle 15 minutes prior to the start of the session. Initially, responding was maintained by a 0.5 mg/kg/infusion of cocaine until responding was stable. The effects of ML375 (30 mg/kg) were assessed at each dose of cocaine after responding was stable. A follow-up session at the same dose of cocaine 24 hours later was assessed to evaluate any long-term effects on behavior.
Lastly, we assessed the effects of ML375 on sugar pellet-maintained responding under a PR schedule of reinforcement. Rats were initially trained to respond for delivery of a sugar pellet under an FR10 schedule before implementing the same PR schedule as described earlier. Stability criteria and training and testing conditions were identical to those described in the study assessing ML375 effects on sugar pellet-maintained responding under an FR schedule of reinforcement.
Rotarod
The effects of ML375 on motor coordination were tested using a rotarod apparatus (model 4600, Ugo Basile, Comerio, Italy) with a rod diameter of 3 cm. During two training sessions that were separated by at least 20 minutes, rats were trained to walk on a rotating rod maintained at a constant speed of 20 revolutions per minute. Only rats that walked on the rotarod for >100 seconds during the second training session advanced to drug treatment, which commenced in the afternoon of the same day. Vehicle or ML375 (3-30 mg/kg i.p.) was administered 15 minutes prior to placing reach rat on the rotarod, and the latency to fall off the rod was measured. The maximum time allotted for each rat to remain on the rotarod was 120 seconds. Previous studies have shown that these parameters are sensitive to D 2 -like DA receptor antagonist-induced disruptions in motor function (Kumar et al. 2009 ).
DATA ANALYSIS
The number of reinforcers per session and response rates (lever presses when a reinforcer was available) were examined for cocaine dose-response curves and sugar pellet-maintained responding. Group means (±SEM) were plotted as a function of ML375 dose and time (15 minutes or 24 hours after treatment) at one dose of cocaine (0.5 mg/kg) or the effect of ML375 treatment (30 mg/ kg) and time at each cocaine dose (0.1-0.75 mg/kg). Repeated measures two-way ANOVAs were used to test for the main effects of ML375 treatment; main effects were followed by Dunnett's post hoc test comparing each test condition with respective vehicle treatment. Data from the rotarod test were analyzed using Kruskal-Wallis ANOVA followed by Dunn's multiple comparisons test. In all cases, P < 0.05 was considered to be significant from respective vehicle conditions. Figure 1a shows the number of reinforcers per session following the administration of ML375 or vehicle when cocaine was self-administered at 0.5 mg/kg/infusion under an FR10 schedule of reinforcement. The number of reinforcers earned during cocaine self-administration sessions (F dose(1, 6) = 7.711, P = 0.0321, F time(2, 12) = 1.468, P = 0.269, F dose × time(2, 12) = 10.02, P = 0.0028) was significantly reduced by 30 mg/kg of ML375, and this reduction persists 24 hours postinjection (all P < 0.05). As shown in Fig. 1b, 30 mg/kg of ML375 significantly reduced sugar pellet-maintained responding, (F dose(1, 6) = 10.43, P = 0.0179, F time(2, 12) = 11.88, P = 0.0014, F dose × time(2, 12) = 10.72, P = 0.0021) following a 15-minute pre-treatment (P < 0.05), but this effect did not persist 24 hours later. Only rats that received both doses of ML375 were included in these analyses. Importantly, ML375 had no effect on inactive lever responses in cocaine selfadministration sessions or in sugar pellet-maintained responding sessions (data not shown) suggesting that reductions in cocaine-lever or sugar pellet-maintained responding were not due to nonspecific effects of ML375 (see Supporting Information Table S1 for response rate data). Figure 1c shows the cumulative number of cocaine infusions earned in 15-minute bins following treatment with vehicle or ML375 across the 120-minute session. Thirty milligrams per kilogram of ML375 significantly reduced the number of reinforcers earned 45-120 minutes after the start of the session on the day of ML375 administration and 24 hours later (F time(7, 42) = 137.6, P < 0.001, F dose(4, 24) = 5.846, P = 0.002; both P < 0.05, F dose × time(28, 168) = 3.67, P < 0.0001). Figure 1d shows the cumulative number of sugar pellets earned after treatment with vehicle or ML375 across the 120-minute session. Ten milligrams per kilogram of ML375 significantly reduced the number of cumulative reinforcers earned during the 30-to 60-minute timepoints, while 30 mg/kg ML375 significantly reduced the cumulative reinforcers from 30 to 120 minutes (F time(7, 210) = 223.4, P < 0.0001; F dose(4, 30) = 5.588, P = 0.0017; F dose × time(28, 210) = 2.532, P < 0.0001). Figure 2a shows the number of reinforcers per session after pre-treatment with 30 mg/kg of ML375 or vehicle as a function of cocaine dose under an FR10 schedule of reinforcement. Rats exhibited a typical biphasic doseresponse curve, and ML375 acutely reduced the number of reinforcers earned during the session (F cocdose(4, 28) = 10.13, P < 0.0001; F ML375treatment(2, 14) = 4.702, P = 0.03; F cocdose × ML375treatment(8, 56) = 1.593, P = 0.15); specifically, ML375 reduced the number of reinforcers at the 0.1-, 0.25-and 0.5-mg/kg/infusion Figure 1 (a) The highest dose of ML375 administered reduces cocaine self-administration (0.5 mg/kg/infusion) under an FR10 schedule of reinforcement, and this reduction persists 24 hours post-injection (inj), n = 7. (b) ML375 reduces the number of sugar pellets earned under the same schedule, but the effect does not persist 24 hours post-injection, n = 7. (c) The cumulative reduction in cocaine infusions after treatment with ML375 (30 mg/kg, triangle symbols) is significant from 45 minutes after the start of the session and continuing to the end of the self-administration session, and this effect is similar 24 hours post-injection. (d) ML375 (10 mg/kg, square symbols) reduces the cumulative number of sugar pellets 30 minutes after the start of the session to 60 minutes, while the highest dose (30 mg/kg) reduces the number of sugar pellets from 30 minutes to the end of the session. All comparisons are to sessions with vehicle pre-treatment (circle symbols).^, 10 mg/kg 15 minutes pre-treatment (PT); *, 30 mg/kg 15 minutes and 24 hours post-injection; P < 0.05 cocaine acutely (P < 0.05). However, at 24 hours after administration, reinforcers were significantly reduced only at the 0.5-mg/kg/infusion cocaine (P < 0.05). Figure 2b shows the response rates during cocaine self-administration sessions following acute vehicle or 30-mg/kg ML375 administration and 24 hours postinjection. Response rates decreased as a function of cocaine dose; ML375 significantly altered response rates for cocaine (F cocdose(4, 28) = 2.76, P = 0.0472; F ML375treatment(2, 14) = 4.561, P = 0.03; F cocdose × ML375treatment(8, 56) = 1.2, P = 0.32). Post hoc analysis revealed effects at 0.25-and 0.5-mg/kg/infusion cocaine (P < 0.05). Only rats with full dose-response curves were included in these analyses. The group dose-response curve does not appear as a typical biphasic dose-response curve as one rat had significantly higher rates of responding (30.41 responses per minute) after vehicle pre-treatment at 0.1 mg/kg/infusion cocaine than the other rats (mean = 4.98 responses per minute). This rat achieved the maximum number of infusions at this dose of cocaine within 45 minutes for each 0.1-mg/kg/infusion cocaine self-administration session. Although group data showed that ML375 reduced the number of cocaine infusions across multiple unit doses of the dose-response curve, variability attributed to individual sensitivity to cocaine, ML375 or a combination thereof was present. Because of the heterogeneity associated with human and nonhuman primate drug self-administration, data are often examined on an individualized basis (e.g. Shoptaw et al. 2003; Freeman & Woolverton 2011; Gould et al. 2017) and by patient stratification in clinical studies (Simpson et al. 1999; Shoptaw et al. 2003) ; we sought to take a similar approach with the present rodent data. Examination of individual dose-response curves as shown in Fig. 3 revealed several important points. First, the doseresponse curves of four rats resembled the classic inverted U-shaped curve and mirrored the group data shown in Fig. 2 . However, in the other four rats, the dose-response curves demonstrated only the ascending or descending limb; moreover, the dose that engendered the peak number of infusions varied (0.1-0.5) as did the maximum number of infusions at the peak. On the basis of these observations alone, it is not surprising that a single dose of a pharmacological agent would not engender the same effect in all rats. However, ML375 reduced cocaine self-administration in at least one dose in six of eight rats. Figure 4a shows the cocaine dose-response curve under a PR schedule of reinforcement. ML375 significantly reduced break points (F cocdose(4, 24) = 29.43, P < 0.0001, F ML375treatment(2, 12) = 14.72, P = 0.0006; F cocdose × ML375treatment(8, 48) = 0.68, P = 0.71), specifically at 0.25 and 0.5 mg/kg/infusion cocaine compared with vehicle (P < 0.05). To determine the selectivity of these effects for drug-related versus nondrug-related reinforcers, the effects on ML375 were also assessed in rats responding under a PR schedule maintained by the delivery of sugar pellets. As shown in Fig. 4b, ML375 did not significantly reduce break points for sugar pellets.
RESULTS
To determine whether reductions in responding may be due to nonspecific sedative/motor effects, we evaluated motor function using the rotarod test following ML375 administration. As shown in Fig. 5 , ML375 had no effect on latency to fall off the rotating rod (F treatment(3, 28) = 1.298, P = 0.7296; n = 7-8 per treatment group).
DISCUSSION
The present study provides the first demonstration of the effects of the highly selective brain penetrant M 5 NAM ML375 on cocaine self-administration in rats. As Figure 5 ML375 does not impair performance on the rotarod test in rats. Latency to fall off the rotarod turning at 20 revolutions per minute was not affected by ML375. Data are represented as mean ± SEM of seven to eight rats per treatment group described, ML375 reduced cocaine self-administration at lower unit doses of cocaine when responding was maintained under both FR and PR schedules of reinforcement. Importantly, the modest reductions in sugar pelletmaintained responding observed with ML375 under an FR schedule were absent under a PR schedule. ML375 did not affect unconditioned motor behavior suggesting that selective negative allosteric modulation (or functional antagonism) of M 5 produces selective effects on cocaine-related behaviors. These data further support future examination of M 5 NAM's for the treatment of multiple aspects of CUD.
By utilizing both FR and PR schedules of reinforcement, we determined that selective inhibition of M 5 by ML375 acutely attenuates both the reinforcing effects and relative reinforcing strength of cocaine as measured by reduced break points. Our findings are consistent with previous M 5 KO mouse studies in which these mice selfadministered less cocaine than wild-type mice under an FR schedule of reinforcement (Fink-Jensen et al. 2003) . At the single dose of 30 mg/kg, ML375 appeared to reduce responding across the cocaine dose-response curve when cocaine was available under the FR10 schedule of reinforcement. In contrast, previous studies using D 2 DA receptor KO mice or D 2 DA receptor antagonists reported rightward shifts of the cocaine dose-response curves, implying that the effects on D 2 DA receptors are surmountable with higher doses of cocaine (Caine et al. 2002; Bari & Pierce 2005) . Compared with a simple FR schedule that only provides information regarding the ability to increase or decrease the reinforcing effects of a stimulus, a PR schedule provides a measure of the reinforcing efficacy of a stimulus and may provide a more relevant measure for the pharmacological augmentation of the reinforcing strength of cocaine (Arnold & Roberts 1997 ). In the current study, ML375 reduced break points at lower doses of cocaine under a PR schedule that had no effects on break points for sugar pellets, a finding consistent with previous M 5 KO studies (Thomsen et al. 2005) . Thus, these data suggest a therapeutic profile that blocks motivation for cocaine potentially without affecting motivation for natural rewards.
While our present data are promising, there are also important caveats. First, our study framework was based on data using genetically modified M 5 KO mice for which there is always the potential for confounding, compensatory changes in gene expression that may contribute to the observed drug-seeking behaviors in these animals (Fink-Jensen et al. 2003; Thomsen et al. 2005) . Second, the effects of ML375 were only determined after acute administration once stable self-administration behavior was acquired. Therefore, in future studies, it will be important to compare the effects of acute and chronic administration of ML375 on all phases of cocaine selfadministration in order to understand the effects of repeated dosing on behavior and underlying changes in mesocorticolimbic reward circuitry. Finally, because the current study focused on evaluating the effects of a single dose of ML375 on the cocaine dose-response curve, it will also be critical in future studies to investigate the effects of a range of doses of ML375 on the cocaine doseresponse curve to confirm the magnitude of any potential downward shift in the FR dose-response curves or whether these effects may be surmounted.
To date the specific site of action for the observed effects of the M 5 NAM ML375 on cocaine-related behaviors remains unknown, one important site involves regulation of potential acute and/or long-term pathophysiological adaptations induced by cocaine within the mesocorticolimbic reward circuitry thought to underlie CUD (Nestler 2005 ). In particular, anatomical studies have revealed that M 5 expression is largely confined to midbrain DA neurons of the VTA, as well as the substantia nigra, within the central nervous system (Weiner et al. 1990; Yasuda et al. 1993) . Moreover, electrophysiological and neurochemical studies have shown increased VTA DA cell firing and extracellular DA release in the NAc following electrical stimulation of the cholinergic projections from the laterodorsal tegmental and pedunculopontine tegmental nuclei to the VTA; effects that are absent in M 5 KO mice (Blaha et al. 1996; Forster & Blaha 2000 Forster et al. 2002; Steidl et al. 2011) . These studies suggest that inhibition of M 5 may be able to reduce cocaine-induced elevations in DA levels in the NAc by blocking acetylcholine-induced activation of VTA DA cell firing. Consistent with this, we found that the effects of the M 5 NAM were similar to previous studies showing that the reinforcing effects and the relative strength of cocaine were decreased in the M 5 KO mice (Fink-Jensen et al. 2003; Thomsen et al. 2005) . Importantly, we saw no effects of the M 5 NAM on behavior maintained by sugar pellets or general motoric output that would be indicative of actions of M 5 expressed on nigrostriatal neurons (Fink-Jensen et al. 2003; Thomsen et al. 2005) .
Because mesolimbic DA circuitry mediates not only the reinforcing effects of drugs of abuse, but also natural rewards such as sugar pellets (Wise 2006; Salamone et al. 2016) , it is possible that modulation of this circuit with an M 5 NAM could adversely affect motivation for sugar pellets. Interestingly, ML375 subtly and transiently affected sugar pellet-maintained responding under an FR, but not a PR schedule of reinforcement. Moreover, effects of ML375 on cocaine self-administration persisted 24 hours after administration although effects of sugar pellet-maintained responding returned to normal by the 24-hour assessment. While selective effects on drugrelated behaviors are more desirable, this transient nature regarding effects on sugar pellet-maintained responding is not novel. In fact, D-amphetamine, a DA releaser that has gained strong support as a treatment for CUD from pre-clinical and clinical studies (Negus & Henningfield 2015) , acutely disrupts sugar pelletmaintained responding on an FR schedule but not on a PR schedule (Czoty et al. 2011; Hutsell et al. 2016) . Further, tolerance rapidly develops to the acute effects on sugar pellet-maintained responding, while reductions in cocaine-maintained responding persist (Czoty et al. 2011 , Hutsell et al. 2016 . D 2 DA receptor antagonists such as haloperidol have also been proposed as possible therapeutics for CUD as they reduce cocaine intake; however, these compounds also negatively affect food reinforcement thus limiting their therapeutic profile (Platt et al. 2002) .
As previously discussed, a number of different pharmacological treatment strategies (Koob et al. 2009) targeting the direct or indirect modulation of mesocorticolimbic reward circuitry have been investigated in clinical populations of cocaine addicts. For example, indirect DA agonists and selective D 2 DA receptor antagonists have been developed as potential substitution or detoxification approaches, respectively, for cocaine addiction (Platt et al. 2002; Shorter et al. 2015; Castells et al. 2016) . However, to date, these DA receptormediated approaches have failed in clinical development because of dose-limiting adverse effects (Shorter et al. 2015) .
Alternatively, indirect modulation of mesocorticolimbic reward circuitry by the gammaaminobutyric acid (GABA) B receptor agonist baclofen and the anti-epileptic agent topiramate with actions at sodium channels and GABA A receptors have both produced promising reductions in cocaine-seeking behaviors in clinical populations and animal models across a broad therapeutic index (Fadda et al. 2003; Johnson 2005; Roberts 2005; Hutsell et al. 2016) . On the basis of the present pre-clinical studies, selective inhibition of M 5 by ML375 appears to also provide a broader therapeutic profile in reducing cocaine taking without eliciting adverse side effects in line with these other treatments that indirectly modulate mesocorticolimbic dopaminergic activity.
In summary, the present findings are the first to report the behavioral effects of a highly selective M 5 mAChR NAM in animal models of drug addiction. Ongoing efforts include the development of more optimized M 5 mAChR NAMs to allow us to further unravel their specific role in modulating mesolimbic DA circuitry and to allow us to assess the effects of repeated dosing on selfadministration as well as utilizing a wider range of doses for testing. While we hypothesize that the present effects on cocaine self-administration are dependent upon M 5 -mediated effects on DA neurons in the VTA, it is possible that M 5 may also be expressed on GABAergic interneurons in the VTA to exert effects on inhibitory signaling in the mesolimbic DA circuitry (Foster et al. 2014) . Previous studies have shown reduced morphineconditioned place preference and less-pronounced morphine-induced withdrawal-like effects in M 5 KO mice (Basile et al. 2002) . Thus, it will be important to further explore the role of M 5 in other aspects of the addiction cycle (e.g. models of relapse and abstinence-related symptoms) and extend our behavioral characterizations to other classes of drugs of abuse (e.g. opioids). The present results suggest that selective modulation of the M 5 mAChRs may be an exciting novel therapeutic approach for treating CUD.
